Latest Governance News

CPT Global Limited reported a 12% revenue increase to $23.1 million for FY2025, driven by growth in the Northern Hemisphere segment, while narrowing its net loss to $706,214. The company is strategically pivoting towards larger markets and investing in technology and talent to fuel future growth.

Aeeris Ltd reported a 27.7% revenue increase to $4.36 million for FY25, driven by proprietary platform launches and expanded client contracts, while posting a net loss of $632,731. The company is poised for operational scale and cash flow positivity in FY26.

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.

The 2025 annual report for SPDR Core Equity ETFs confirms compliance with accounting standards and provides detailed unitholder data, underscoring the funds' robust governance and market position.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

333D Limited has reported a remarkable turnaround for the year ended June 2025, posting a profit after tax of $143,777 on the back of a 426% revenue increase driven by its digital asset management strategy. The company also adopted a Bitcoin Treasury Management Policy, signaling a new phase in its financial approach.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Aeris Resources Limited reported a robust financial turnaround for FY25, posting a $45.2 million profit and a 68% rise in adjusted EBITDA, underpinned by steady copper and gold production and strategic refinancing.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Alternative Investment Trust (ASX, AIQ) reported a robust half-year profit increase of 183%, driven by strong gains in its Warana-managed portfolio. The Trust also announced a significant $44.6 million rights issue to fund further investments.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.